DURECT Corporation

Rentabilité sur six mois: -19.08%
Rendement en dividendes: 0%
Secteur: Healthcare

0.615 $

0 $ 0%
0.4999 $
1.67 $

paper.min_max_per_year

Calendrier des promotions DURECT Corporation

À propos de l'entreprise DURECT Corporation

DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. It also develops larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis. In addition, the company offers POSIMIR, a post-surgical pain product to deliver bupivacaine over three days in adults; and Methydur to treat attention deficit hyperactivity disorder. It markets and sells its ALZET lines through direct sales force in the United States, as well as through a network of distributors in Japan, Europe, and internationally. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; and Innocoll Pharmaceuticals Limited. DURECT Corporation was incorporated in 1998 and is headquartered in Cupertino, California.

Paramètres de base

IPO date
2000-09-28
ISIN
US2666051048
Industry
Pharmaceuticals
Sector
Health Care
Валюта
usd
Валюта отчета
usd
Сайт

Grade

Sous-estimation
Nom Signification Grade
P/S 12.95 1
P/BV 2.88 6
P/E 0 0
Efficacité
Nom Signification Grade
ROA -26.2 0
ROE -68.52 0
ROIC 0 0
Dividendes
Nom Signification Grade
Rendement en dividendes 0 0
DSI 0 0
Croissance moyenne du dividende 0 0
Devoir
Nom Signification Grade
Debt/EBITDA -0.1166 10
Debt/Ratio 0.1202 10
Debt/Equity 1.01 8
Impulsion de croissance
Nom Signification Grade
Rentabilité Revenue, % -93.25 0
Rentabilité Ebitda, % 56.3 7
Rentabilité EPS, % 112.85 10

paper.price.prices

Prix Common.min. Common.max. Changement paper.changes_in_industry paper.changes_in_index
common.calendar.number_days.1 0.615 $ 0 $ 0 $ 0 % 0 % 0 %
common.calendar.number_days.7d 0.6 $ 0 $ 0 $ 2.5 % 0 % 0 %
common.calendar.number_days.30d 0.544 $ 0.541 $ 0.64 $ 13.05 % 0 % 0 %
common.calendar.number_days.90d 0.749 $ 0.4999 $ 0.8 $ -17.89 % 0 % 0 %
common.calendar.number_days.180d 0.76 $ 0.4999 $ 0.87 $ -19.08 % 0 % 0 %
common.calendar.number_days.1y 1.39 $ 0.4999 $ 1.67 $ -55.76 % 0 % 0 %
common.calendar.number_days.3y 7.83 $ 0.425 $ 8.72 $ -92.15 % 0 % 0 %
common.calendar.number_days.5y 2.32 $ 0.3764 $ 8.72 $ -73.43 % 0 % 0 %
common.calendar.number_days.10y 0.3764 $ 0.3764 $ 8.72 $ 163.39 % 0 % 0 %
common.calendar.number_days.ytd 0.7502 $ 0.4999 $ 0.87 $ -18.02 % 0 % 0 %

Principaux propriétaires

Entreprises similaires



Gestion d'entreprise

Superviseur Titre d'emploi Paiement Année de naissance
Dr. James E. Brown D.V.M. Co-Founder, CEO, President & Director 633.46k 1957 (68 années)
Ms. Judy R. Joice Senior Vice President of Operations & Corporate Quality Assurance 451.82k 1957 (68 années)
Dr. Norman L. Sussman M.D. Chief Medical Officer 471.71k 1953 (72 année)
Mr. Timothy M. Papp M.B.A. CFO & Secretary 427.62k 1976 (49 années)
Ms. Jian Li M.B.A. Senior VP of Finance, Corporate Controller & Secretary 297.08k 1970 (55 années)
Dr. WeiQi Lin M.D., Ph.D. Executive VP of Research & Development and Principal Scientist N/A
Mr. Keith L. Lui M.B.A. Senior Vice President of Business Development, Commercial & Medical Affairs N/A
Dr. Su Il Yum Ph.D. Executive Officer 331.74k 1939 (86 années)

Informations sur l'entreprise

Adresse: United States, Cupertino. CA -, 10260 Bubb Road - Ouvrir dans google maps, Ouvrir les cartes yandex
Site web: https://www.durect.com